SCHEMBL4773101

SCHEMBL4773101

COc1ccc2cc(-c3ccccc3OC)nc(Cl)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.51
HSP90AB1 P08238 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.45
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
AR P10275 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
CYP17A1 P05093 2/20 0.42
CYP11B1 P15538 2/20 0.42
CYP11B2 P19099 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
CYP2D6 P10635 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773825 0.85 HSP90AA1 (0.56) HSP90AA1HSP90AB1SMN1; SMN2KDM4EMEN1
SCHEMBL4774988 0.83 CYP2D6 (0.53) KDM4EMEN1KMT2APOLBALDH1A1
SCHEMBL4765203 0.83 MEN1 (0.55) SMN1; SMN2KDM4EMEN1KMT2APOLB
SCHEMBL4766668 0.81 KDM4E (0.58) SMN1; SMN2KDM4EMEN1KMT2AALDH1A1
SCHEMBL4766383 0.75 ADORA2A (0.46) HSP90AA1HSP90AB1SMN1; SMN2KDM4EMEN1
SCHEMBL15578480 0.74 KDM4E (0.72) HSP90AA1HSP90AB1SMN1; SMN2KDM4EMEN1
SCHEMBL29613286 0.74 KDM4E (0.53) SMN1; SMN2KDM4EMEN1KMT2APOLB
SCHEMBL2155887 0.74 CYP17A1 (0.49) HSP90AA1HSP90AB1SMN1; SMN2KDM4EMEN1
SCHEMBL29773842 0.74 CYP17A1 (0.49) HSP90AA1HSP90AB1SMN1; SMN2KDM4EMEN1
SCHEMBL2154762 0.73 NPC1 (0.64) SMN1; SMN2KDM4EALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 HSP90AA1 2106/4885HSP90AB1 2551/4885SMN1; SMN2 27/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 HSP90AA1 2132/4885HSP90AB1 2339/4885SMN1; SMN2 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.